论文部分内容阅读
目的:评价奥美沙坦酯治疗原发性高血压的疗效和安全性。方法:选择轻、中度高血压患者64例,随机分为奥美沙坦酯治疗组(n=34例)和缬沙坦对照组(n=30例),每日1次口服奥美沙坦酯20 mg或缬沙坦80 mg,2周后如舒张压≥90mmHg,则剂量加倍,进行8周的临床观察。结果:两组患者血压均得到明显降低(P<0.01),奥美沙坦酯组,总有效率88.2%;缬沙坦组总有效率86.7%。两组比较无统计学差异(P>0.05)。结论:奥美沙坦酯治疗原发性高血压疗效显著,与进口同类药缬沙坦相当,不良反应少,安全有效。
Objective: To evaluate the efficacy and safety of olmesartan medoxomil in the treatment of essential hypertension. Methods: Sixty-four patients with mild to moderate hypertension were randomly divided into two groups: olmesartan medoxomil group (n = 34) and valsartan control group (n = 30) 20 mg or valsartan 80 mg. After two weeks, if the diastolic blood pressure is greater than or equal to 90 mmHg, the dose is doubled and clinical observation for 8 weeks is performed. Results: The blood pressure was significantly decreased in both groups (P <0.01). In the olmesartan medoxomil group, the total effective rate was 88.2%. The total effective rate in the valsartan group was 86.7%. There was no significant difference between the two groups (P> 0.05). Conclusion: Olmesartan Medoxomil is effective in treating essential hypertension. It is equivalent to imported valsartan, less adverse reactions and safe and effective.